Laura B Ramsey

List of Publications by Year
in descending order

106 papers	3,618 citations	159585 30 h-index	144013 57 g-index
110 all docs	110 docs citations	110 times ranked	4888 citing authors

#	Article	IF	Citations
1	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology and Therapeutics, 2014, 96, 423-428.	4.7	379
2	The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clinical Pharmacology and Therapeutics, 2012, 92, 112-117.	4.7	294
3	Rare versus common variants in pharmacogenetics: *SLCO1B1* variation and methotrexate disposition. Genome Research, 2012, 22, 1-8.	5.5	232
4	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 2013, 121, 898-904.	1.4	174
5	*Ebf1* or *Pax5* haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1135-1149.	8.5	140
6	RAG-1 and ATM coordinate monoallelic recombination and nuclear positioning of immunoglobulin loci. Nature Immunology, 2009, 10, 655-664.	14.5	130
7	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	21.4	126
8	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist, 2018, 23, 52-61.	3.7	123
9	The Clinical Pharmacogenetics Implementation Consortium Guideline for *SLCO1B1*, *ABCG2*, and *CYP2C9* genotypes and Statin‑Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
10	Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors. Cell Reports, 2013, 5, 1047-1059.	6.4	116
11	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood, 2014, 124, 1266-1276.	1.4	84
12	Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. Frontiers in Pharmacology, 2019, 10, 99.	3.5	70
13	Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. European Journal of Cancer, 2014, 50, 2685-2694.	2.8	67
14	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nature Immunology, 2017, 18, 694-704.	14.5	67
15	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood, 2015, 126, 69-75.	1.4	64
16	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Human Molecular Genetics, 2012, 21, 4793-4804.	2.9	56
17	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood, 2016, 127, 558-564.	1.4	56
18	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genetics in Medicine, 2019, 21, 2255-2263.	2.4	53

#	Article	IF	Citations
19	Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods. Clinical Pharmacology and Therapeutics, 2012, 92, 360-365.	4.7	51
20	Genome‐Wide Study Links *PNPLA3* Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clinical Pharmacology and Therapeutics, 2017, 102, 131-140.	4.7	50
21	Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. Current Problems in Pediatric and Adolescent Health Care, 2018, 48, 40-49.	1.7	49
22	Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine. Clinical Pharmacology and Therapeutics, 2019, 105, 49-52.	4.7	48
23	Escitalopram in Adolescents With Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	48
24	B Cell Receptor Basal Signaling Regulates Antigen-Induced Ig Light Chain Rearrangements. Journal of Immunology, 2008, 180, 4728-4741.	0.8	40
25	Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model. PLoS ONE, 2016, 11, e0151433.	2.5	40
26	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28040.	1.5	38
27	IL-7 Functionally Segregates the Pro-B Cell Stage by Regulating Transcription of Recombination Mediators across Cell Cycle. Journal of Immunology, 2012, 188, 6084-6092.	0.8	37
28	CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 340-347.	1.3	35
29	Opportunity for Genotype‐Guided Prescribing Among Adult Patients in 11 US Health Systems. Clinical Pharmacology and Therapeutics, 2021, 110, 179-188.	4.7	35
30	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Network Open, 2020, 3, e2029411.	5.9	34
31	Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 348-361.	1.3	32
32	MTXPK.org: A Clinical Decision Support Tool Evaluating High‐Dose Methotrexate Pharmacokinetics to Inform Post‐Infusion Care and Use of Glucarpidase. Clinical Pharmacology and Therapeutics, 2020, 108, 635-643.	4.7	32
33	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine, 2021, 23, 2335-2341.	2.4	32
34	Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies. Cancers, 2021, 13, 2837.	3.7	31
35	PharmGKB summary: sertraline pathway, pharmacokinetics. Pharmacogenetics and Genomics, 2020, 30, 26-33.	1.5	26
36	Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 660-664.	0.5	26

#	ARTICLE	IF	CITATIONS
37	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia, 2017, 31, 1325-1332.	7.2	25
38	Functional Characterization of Liver Enhancers That Regulate Drug-Associated Transporters. Clinical Pharmacology and Therapeutics, 2011, 89, 571-578.	4.7	24
39	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Pediatric Blood and Cancer, 2019, 66, e27618.	1.5	24
40	Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. Pharmacotherapy, 2017, 37, 1172-1190.	2.6	23
41	Gene-Based Dose Optimization in Children. Annual Review of Pharmacology and Toxicology, 2020, 60, 311-331.	9.4	23
42	Learning Health Systems as Facilitators of Precision Medicine. Clinical Pharmacology and Therapeutics, 2017, 101, 359-367.	4.7	22
43	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 50-52.	4.7	22
44	Clinical implementation of pharmacogenetics and model‐informed precision dosing to improve patient care. British Journal of Clinical Pharmacology, 2022, 88, 1418-1426.	2.4	21
45	Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology American Society of Hematology Education Program, 2013, 2013, 126-130.	2.5	20
46	*Sleeping Beauty* Screen Identifies *RREB1* and Other Genetic Drivers in Human B-cell Lymphoma. Molecular Cancer Research, 2019, 17, 567-582.	3.4	19
47	PharmVar GeneFocus: *SLCO1B1*. Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	4.7	18
48	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	1.5	17
49	Pharmacogenetics of treating pediatric anxiety and depression. Pharmacogenomics, 2019, 20, 867-870.	1.3	17
50	Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clinical and Translational Science, 2021, 14, 692-701.	3.1	17
51	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 541-551.	2.5	16
52	The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. Journal of Personalized Medicine, 2021, 11, 615.	2.5	16
53	Substrain-specific differences in survival and osteonecrosis incidence in a mouse model. Comparative Medicine, 2012, 62, 466-71.	1.0	16
54	Association of *SLCO1B1* *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients. ACR Open Rheumatology, 2019, 1, 58-62.	2.1	15

#	ARTICLE	IF	CITATIONS
55	A comprehensive evaluation of collapsing methods using simulated and real data: excellent annotation of functionality and large sample sizes required. Frontiers in Genetics, 2014, 5, 323.	2.3	14
56	Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 1309-1318.	0.5	14
57	Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clinical and Translational Science, 2022, 15, 371-383.	3.1	13
58	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS ONE, 2015, 10, e0135134.	2.5	13
59	Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways. Immunology Letters, 2011, 135, 74-77.	2.5	12
60	Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors. Frontiers in Pharmacology, 2021, 12, 749692.	3.5	12
61	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenetics and Genomics, 2014, 24, 263-271.	1.5	9
62	CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 56-62.	1.3	9
63	Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. Clinical Pharmacology and Therapeutics, 2021, 110, 589-594.	4.7	9
64	Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications. Frontiers in Pharmacology, 2022, 13, 833217.	3.5	8
65	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. PLoS ONE, 2019, 14, e0216328.	2.5	7
66	Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations. Depression and Anxiety, 2020, 37, 747-759.	4.1	7
67	Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series. Clinical and Translational Science, 2022, 15, 610-618.	3.1	7
68	Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers. Clinical Pharmacology and Therapeutics, 2019, 106, 298-301.	4.7	6
69	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clinical Pharmacology and Therapeutics, 2021, 110, 559-562.	4.7	6
70	Thyroid Function Screening in Children and Adolescents With Mood and Anxiety Disorders. Journal of Clinical Psychiatry, 2019, 80, .	2.2	6
71	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	1.4	6
72	Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial. Journal of Personalized Medicine, 2021, 11, 1188.	2.5	6

#	Article	IF	Citations
73	Racial Differences in Escitalopram/Citalopram-Related Weight Gain in Children and Adolescents: A Natural Language Processing-Based Electronic Medical Record Study. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 162-163.	1.3	5
74	The Influence of Pharmacodynamic Genes on Fluoxetine Response in Pediatric Anxiety and Depressive Disorders. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 276-277.	1.3	5
75	Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians. Pediatric Research, 2022, 91, 529-538.	2.3	5
76	SLCO1B1 *15 allele is associated with methotrexate–induced nausea in pediatric patients with inflammatory bowel disease. Clinical and Translational Science, 2021, , .	3.1	5
77	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. Blood, 2012, 120, 2466-2466.	1.4	5
78	Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 267-272.	1.3	4
79	Planning and Conducting a Pharmacogenetics Association Study. Clinical Pharmacology and Therapeutics, 2021, 110, 688-701.	4.7	4
80	Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implementation Science Communications, 2022, 3, 52.	2.2	4
81	Toward pharmacogenetic SLCO1B1–guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. Clinical and Translational Science, 2021, 14, 2267-2277.	3.1	3
82	<i>Letter to the Editor:</i> Sleep Disturbances in Selective Serotonin Reuptake Inhibitor-Treated Youth with Anxiety Disorders and Obsessive Compulsive Disorder—A Bayesian Hierarchical Modeling Meta-Analysis. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 387-388.	1.3	3
83	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 530-530.	1.4	3
84	Editorial: Beyond Red Light, Green Light: Examining the Role of Pharmacogenomics in Evidence-Based Care in Child and Adolescent Psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, 61, 29-31.	0.5	3
85	21.3 Cyp2C19 Influence on Escitalopram Efficacy and Tolerability in Youth With Anxiety and Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S301.	0.5	2
86	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. Blood, 2015, 126, 3714-3714.	1.4	2
87	Pediatric Psychopharmacology for Depressive and Anxiety Disorders. Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	2
88	A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder. Journal of Personalized Medicine, 2022, 12, 1006.	2.5	2
89	6.38 Pharmacogenomics of Methylphenidate Side Effects in Children With Attention-Deficit/Hyperactivity Disorder (ADHD). Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, S289.	0.5	1
90	CYP2C19 Metabolizer Status Does Not Influence the Safety or Efficacy of Pentamidine. Biology of Blood and Marrow Transplantation, 2020, 26, S94.	2.0	1

#	Article	IF	Citations
91	The need for a refined understanding of CYP2D6 in second-generation antipsychotic outcomes in children and adolescents. Pharmacogenomics, 2021, 22, 447-450.	1.3	1
92	*CYP2D6*9* and **41*: Does the Activity Value Assigned to these Alleles Need to be Reduced to more Accurately Predict Phenotype?. Clinical Pharmacology and Therapeutics, 2022, 111, 1208-1211.	4.7	1
93	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 60-60.	1.4	1
94	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3701-3701.	1.4	1
95	A Single SNP in ADRB2 Halves the Opioid Requirement for Mucositis Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S60-S61.	2.0	0
96	21.1 Overview of Pharmacogenetics and Implementation in a Large Child Psychiatry Unit. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S300-S301.	0.5	0
97	Pharmacogenetic Testing and Antidepressants in Youth With Depressive and Anxiety Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S300.	0.5	0
98	*Ebf1* or *Pax5* haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. Journal of Cell Biology, 2011, 193, i13-i13.	5.2	0
99	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. Blood, 2011, 118, 571-571.	1.4	0
100	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. Blood, 2012, 120, 3560-3560.	1.4	0
101	Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children. , 2014, , .		0
102	A Murine Model of Asparaginase Allergy. Blood, 2014, 124, 2295-2295.	1.4	0
103	Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia. Blood, 2015, 126, 250-250.	1.4	0
104	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	1.4	0
105	Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1970-1970.	1.4	0
106	Influence of albumin and methotrexate clearance on high-dose methotrexate-induced mucositis.. Journal of Clinical Oncology, 2022, 40, e15081-e15081.	1.6	0